Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Syndecan-1 (CD138) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:CD138
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RGP009R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma, Cell culture supernatant

Sample Requirements

100 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

8–256 ng/ml

Limit of Detection

< 2.56 ng/ml

Summary

Research topic

Cell surface proteins (sCD), Oncology

Summary

Syndecans are a transmembrane protein family within the heparin sulphate proteoglycan group that interact with many different molecules of the immune system through their heparin sulphate chains. The mammalian syndecan family consists of 4 proteins; syndecan 1 to 4 each encoded by very distinct genes. In adult tissues syndecan 1 (CD138) is predominantly expressed by epithelial cells and plasma cells (both normal and malignant) and currently considered the most reliable surface marker for plasma cells. In addition CD138 is also expressed on pre and immature B cells however this is regulated by IL-6 and LPS stimulation. Syndecan 1 has previously been shown to participate in cell to cell interactions, organ development, vessel formation and tissue regeneration following injury. CD138 is regularly cleaved from the membrane and as a consequence high levels of soluble CD138 are found in the blood, which can be easily detected using a CD138 specific ELISA. Via its heparin sulphate chains CD138 binds to and modulates the activity of a wide range of molecules involve in inflammation including chemokines, growth factors, selectins and other adhesion molecules. CD138 can also act as a receptor for collagen, fibronectin, thromobospondin and tenascin therefore involved in cell matrix adhesion. CD138 has been shown to mediate the binding of myeloma cells to type I collagen, and inhibits tumour cell invasion into collagen gels. As CD138 has been shown to have important effects on tumour cell growth, survival, adhesion and invasion syndecan-1 may be an important regulator in cancer biology.

Product References (17)

References

  • Annecke T, Chappell D, Chen C, Jacob M, Welsch U, Sommerhoff CP, Rehm M,Conzen PF, Becker BF. Sevoflurane preserves the endothelial glycocalyx againstischaemia-reperfusion injury. Br J Anaesth. 2010 Apr;104(4):414-21. doi:10.1093/bja/aeq019. Epub 2010 Feb 19. PubMed PMID: 20172938. See more on PubMed
  • Bruegger D, Jacob M, Rehm M, Loetsch M, Welsch U, Conzen P, Becker BF. Atrial natriuretic peptide induces shedding of endothelial glycocalyx in coronaryvascular bed of guinea pig hearts. Am J Physiol Heart Circ Physiol. 2005Nov;289(5):H1993-9. Epub 2005 Jun 17. PubMed PMID: 15964925. See more on PubMed
  • Bruegger D, Rehm M, Abicht J, Paul JO, Stoeckelhuber M, Pfirrmann M, Reichart B, Becker BF, Christ F. Shedding of the endothelial glycocalyx during cardiacsurgery: on-pump versus off-pump coronary artery bypass graft surgery. J ThoracCardiovasc Surg. 2009 Dec;138(6):1445-7. doi: 10.1016/j.jtcvs.2008.07.063. Epub2009 Feb 4. PubMed PMID: 19660323. See more on PubMed
  • Celie JW, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ter Wee PM, Florquin S, van den Born J. Tubulointerstitial heparan sulfate proteoglycan changes inhuman renal diseases correlate with leukocyte influx and proteinuria. Am JPhysiol Renal Physiol. 2008 Jan;294(1):F253-63. Epub 2007 Nov 21. PubMed PMID:18032547. See more on PubMed
  • Chappell D, Jacob M, Hofmann-Kiefer K, Rehm M, Welsch U, Conzen P, Becker BF. Antithrombin reduces shedding of the endothelial glycocalyx followingischaemia/reperfusion. Cardiovasc Res. 2009 Jul 15;83(2):388-96. doi:10.1093/cvr/cvp097. Epub 2009 Mar 22. PubMed PMID: 19307232. See more on PubMed
  • Iwata H, Matsuo K, Takeuchi K, Kishi Y, Murashige N, Kami M. High incidencesof malignant lymphoma in patients infected with hepatitis B or hepatitis C virus.Haematologica. 2004 Mar;89(3):368-70. PubMed PMID: 15020283. See more on PubMed
  • Jánosi J, Sebestyén A, Mikala G, Németh J, Kiss Z, Vályi-Nagy I. Solublesyndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma. Haematologica. 2004 Mar;89(3):370-1. PubMed PMID: 15020284. See more on PubMed
  • Kliment CR, Englert JM, Gochuico BR, Yu G, Kaminski N, Rosas I, Oury TD.Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.J Biol Chem. 2009 Feb 6;284(6):3537-45. doi: 10.1074/jbc.M807001200. Epub 2008Dec 9. PubMed PMID: 19073610; PubMed Central PMCID: PMC2635035. See more on PubMed
  • Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V,Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Rème T, Goldschmidt H,Klein B. Heparanase influences expression and shedding of syndecan-1, and itsexpression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007 Jun 1;109(11):4914-23. Epub 2007 Mar 5. PubMed PMID:17339423; PubMed Central PMCID: PMC2268882. See more on PubMed
  • Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, RibattiD, Vacca A. Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia:correlation with the extent of angiogenesis and disease-progression risk in earlydisease. Leuk Lymphoma. 2006 Jun;47(6):1034-40. PubMed PMID: 16840194. See more on PubMed
  • Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, Chappell D,Stoeckelhuber M, Welsch U, Reichart B, Peter K, Becker BF. Shedding of theendothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007 Oct 23;116(17):1896-906. Epub 2007 Oct8. PubMed PMID: 17923576. See more on PubMed
  • Schaar CG, Vermeer HJ, Wijermans PW, Huisman W, le Cessie S, Kluin-NelemansHC. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.Haematologica. 2005 Oct;90(10):1437-8. PubMed PMID: 16219583. See more on PubMed
  • Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A,Borset M. Serum syndecan-1: a new independent prognostic marker in multiplemyeloma. Blood. 2000 Jan 15;95(2):388-92. Erratum in: Blood 2000 Apr1;95(7):2197. PubMed PMID: 10627439. See more on PubMed
  • Snoeijs MG, Vink H, Voesten N, Christiaans MH, Daemen JW, Peppelenbosch AG,Tordoir JH, Peutz-Kootstra CJ, Buurman WA, Schurink GW, van Heurn LW. Acuteischemic injury to the renal microvasculature in human kidney transplantation. AmJ Physiol Renal Physiol. 2010 Nov;299(5):F1134-40. doi:10.1152/ajprenal.00158.2010. Epub 2010 Sep 1. PubMed PMID: 20810613. See more on PubMed
  • Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, KanakisI, Dalas E, Karamanos NK, Sundan A, Hjerpe A. Serglycin constitutively secretedby myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem. 2006 Nov 17;281(46):35116-28. Epub 2006 Jul 26. PubMed PMID: 16870619. See more on PubMed
  • Thiara AS, Andersen VY, Videm V, Mollnes TE, Svennevig K, Hoel TN, Fiane AE.Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion. 2010 Jan;25(1):9-16. doi: 10.1177/0267659110362822. Epub 2010 Feb 19. PubMed PMID: 20172900. See more on PubMed
  • Thiara AS, Mollnes TE, Videm V, Andersen VY, Svennevig K, Kolset SO, Fiane AE.Biocompatibility and pathways of initial complement pathway activation withPhisio- and PMEA-coated cardiopulmonary bypass circuits during open-heartsurgery. Perfusion. 2011 Mar;26(2):107-14. doi: 10.1177/0267659110392438. Epub2010 Dec 22. PubMed PMID: 21177724. See more on PubMed
Related Products Docs